

Review Article

Medicinal Plants with antihypertensive activity. A review

Abstracts

The medical term for elevated blood pressure is hypertension (HTN). It is risky because it puts too much strain on the heart and causes atherosclerosis, which is the hardening of the arteries, in addition to raising the risk of heart disease and stroke. Other diseases like congestive heart failure, renal disease, and blindness can also arise due to HTN. Standard antihypertensive drugs frequently have a number of adverse effects. About 75 to 80 percent of the world's population, mostly in underdeveloped nations, use herbal medicines for primary health care because of its higher tolerance by the human body and fewer adverse effects. Research on native plants with hypotensive and antihypertensive therapeutic benefits has received a lot of focused attention during the past three decades. It has been proved by previous researchers that some of these medicinal herbs have hypotensive and antihypertensive properties. To evaluate the efficacy and clarify the safety profile of such herbal treatments for their antihypertensive potential, more scientific study along with Ayurveda expertise must be combined with modern medicine.

Key words: Antihypertensive, herbs, hypotensive, hypertension, medicinal plants

Introduction

Hypertension (HTN) is a chronic medical condition that leads to elevated blood pressure in the arteries. In the world, high blood pressure is the main reversible risk factor for cardiovascular disease (CVD) and all-cause mortality (Li et al., 2020), (Ge et al., 2012). There were 1.39 billion adults worldwide in 2010, and hypertension affected 31.1% of them (Mills et al., 2020), (Mills et al., 2016). HTN is defined as when the systolic and/or diastolic blood pressures are greater than 140 mmHg and 90 mmHg, respectively. The aging of the population and increased exposure to lifestyle risk factors, such as bad diets (high salt and low potassium intake and lack of physical activity), are both contributing to an increase in the prevalence of hypertension globally (Mills et al., 2020), (Samadian et al., 2016). Globally, the prevalence of hypertension has changed, although not consistently. High-income nations (HICs) had a little decline in the prevalence of hypertension during the past two decades, while low- and middle-income nations (LMICs) saw large rises (Schutte et al., 2021), (Bowry et al., 2015).

These differences in hypertension prevalence patterns indicate that LMIC health care systems may have to deal with a significant burden of infectious diseases as well as a fast rising burden of cardiovascular diseases caused by high blood pressure. One billion people worldwide suffer from hypertension, the most prevalent cardiovascular disease, which continues to be the main cause of 9.4 million deaths each year and contribute significantly to the global burden of disease (Guwatudde et al., 2015), (Bedane, 2018). The number of people with hypertension is expected to increase to 1.5 billion by 2025 from an estimated 972 million in 2000, 65% of whom resided

in the developing countries (Guwatudde et al., 2015). If hypertension is not treated, it can have devastating complications, including heart attack, stroke, cardiac failure, and renal failure, among others. Many studies suggest that hypertension is a major issue in sub-Saharan Africa (SSA), where it has been reported to be as high as 38% in some groups (Guwatudde et al., 2015), (Ogah and Rayner, 2013). Ten to twenty million of the over 650 million people in SSA are thought to suffer hypertension (Desormais et al., 2019), (Mv & Mwinuka, 2021), (Guwatudde et al., 2015). But many SSA nations still lack comprehensive fundamental information on the prevalence of hypertension and how it is spread among the various SSA populations (Guwatudde et al., 2015). Several studies have also examined the prevalence of pre-hypertension and the percentage of people with hypertension who are aware of their condition. In Nigeria, there were an estimated 20.8 million cases of hypertension among adults aged at least 20 in 2010. The prevalence was 28.0% (24.6, 31.9), with men and women experiencing 30.7% (24.9, 33.7) and 25.2% (22.7, 31.9), respectively, of the disease (Ajayi et al., 2019), (Adeloye et al., 2015). Also, it is predicted that by 2030 there will be 39.1 million cases of hypertension among adults aged at least 20 years, with prevalence rates of 30.8% (24.5, 33.7) for both sexes - 32.6% (27.3, 38.2) for men and 29.0% (21.9-32.2) for women (Ajayi et al., 2019). Thus, the urgent need for a long-term solution. The majority of deaths from non-communicable diseases (NCDs) are attributable to cardiovascular disorders (48%) in the US. Raised blood pressure is one of the top physiological and behavioral risk factors for mortality, and it is responsible for 13% of all deaths worldwide. According to reports, hypertension ranks fourth among causes of early death in industrialized nations and seventh in underdeveloped nations. According to earlier studies, hypertension is one of the main causes of death and disability and is fast becoming more common in emerging nations. Hypertension is classified as either primary (essential) or secondary. Essential or primary HTN is the most common type of HTN, affecting 90 to 95% of hypertensive patients (Princewel et al., 2019), (Khan et al., 2016). Despite the lack of a clear cause, there are numerous contributing factors, including a sedentary lifestyle, stress, visceral obesity, and potassium deficiency (hypokalemia) (Tabassum and Ahmad, 2011). Age-related risk is also higher (Barton et al., 2016), the presence of certain inherited genetic variants and a family history of HTN (Zhu et al., 2018), (Tabassum and Ahmad, 2011). An additional risk factor is an increase in renin, an enzyme released by the kidney (Nandhini, 2014) similar to overactive sympathetic nervous system (Saxena et al., 2018). Insulin resistance may also influence HTN, which is a part of syndrome X, generally known as the metabolic syndrome. High fructose corn syrup-containing diets may raise one's risk of acquiring HTN (Ferder et al., 2010), (Le et al., 2012). The other 5 to 10% of instances, known as secondary HTN, are brought on by additional disorders that affect the kidneys, arteries, heart, or endocrine system (Tabassum and Ahmad, 2011). By definition, secondary HTN has a known cause. Since this type is treated differently from essential HTN by addressing the underlying cause of the raised BP. The pathophysiological mechanisms that control blood plasma volume and cardiac function, including the hormone-regulatory endocrine system are compromised in HTN. Some common and well-known secondary causes of HTN include Cushing's syndrome, in which the adrenal glands generate too much of the hormone cortisol (Tabassum and Ahmad, 2011). HTN is also brought on by other illnesses that alter hormone levels, including cancer of the adrenal gland, hyperthyroidism, and hypothyroidism. In addition, metabolic disorders, pre-eclampsia during pregnancy, coarctation of the aorta, kidney

disease, and other congenital defects are typical secondary causes of hypertension. Chronic HTN is a major contributor to chronic kidney failure and one of the risk factors for stroke, heart attack, heart failure, and arterial aneurysm (Tabassum and Ahmad, 2011), (Anthony and Sliwa, 2016). Life expectancy is decreased with moderate arterial BP increase. Changes in food, lifestyle, and medication can all help to control blood pressure better and lower the chance of any ensuing health issues. The systolic and diastolic BPs are another factor used to categorize HTN. The blood pressure in vessels while the heart is beating is known as systolic blood pressure. The pressure between heartbeats is known as diastolic BP. A person is categorized as having pre-HTN or HTN if their systolic or diastolic blood pressure readings are higher above the considered normal ranges for their age. HTN is divided into a number of subcategories, including stage I, stage II, and isolated systolic HTN (Tabassum and Ahmad, 2011). Individual systolic HTN, which is frequent in senior people, is defined as having a high systolic pressure with a normal diastolic pressure. A patient's resting blood pressure readings from two or more clinic visits are averaged to arrive at these groupings. If a person's blood pressure is continuously at least 140 mmHg systolic or 90 mmHg diastolic and they are older than 50, they are considered to have HTN. Further treatment is necessary for patients whose blood pressure is greater than 130/80 mmHg and who also have diabetes or kidney disease. HTN is also categorized as resistant if treatments do not bring BP down to normal levels (Viera, 2012). Exercise-related hypertension is an abnormally high BP increase during exercise (Kovacs et al., 2017). Systolic levels during activity should be between 200 and 230 mmHg, which is considered normal (Holmqvist et al., 2012). Exercise HTN may signal a person's risk of acquiring HTN at rest (Fagard, 2011).

Pathophysiology of hypertension

Most people understand the majority of secondary HTN-related processes; on the other hand, symptoms linked with essential (primary) HTN less characterized. What is known is that early in the disease's progression, cardiac output is elevated with normal total peripheral resistance (TPR). Eventually, cardiac output returns to normal levels, while TPR rises. Three theories have been put out to explain this, and they are as follows:

- Lack of sodium excretion by the kidneys causes the release of natriuretic factors like atrial natriuretic factor, which raises TPR as a side effect (M. Singh et al., 2010), (Tabassum and Ahmad, 2011).
- Vasoconstriction, salt and water retention, and hyperactivity of the renin-angiotensin system occur. HTN is brought on by an increase in blood volume (Pimenta and Oparil, 2009).
- Heightened stress responses due to an overactive sympathetic nervous system (Tuck, 1986), (Takahashi, 2008).

Another well-known fact about HTN is that it is highly heritable and polygenic (produced by multiple genes), and a few potential genes have been proposed as the disease's etiological factors (Sharma et al., 2012), (Tabassum and Ahmad, 2011). The study of the connection between prolonged endothelium injury and essential HTN has gained favor recently among experts on the disease. To what extent long-term increased BPs or whether they occur before the onset of HTN

is yet unknown cause endothelial alterations. For coronary artery disease, stroke, and renal failure, HTN is a significant independent risk factor. The risk of a fatal coronary event doubles for every 20 mmHg rise in systolic blood pressure and 10 mmHg rise in diastolic blood pressure over the range of 115/75 to 185/115 mmHg (Sharma et al., 2012), (Ghadieh and Saab, 2015). In attempt to lessen these negative effects, the American Heart Association and other groups are now urging more aggressive BP goals for many persons with HTN. Diuretics, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, vasodilators, and other medications are frequently used to treat HTN.

Anti-hypertensive drugs.

There are both pharmaceutical and non-pharmacological methods for managing hypertension. While non-pharmacologic therapies involve changing one's way of life to manage high blood pressure, pharmacologic treatment involves the use of anti-hypertensive medications to lower blood pressure. To obtain optimal blood pressure control, one must alter one's lifestyle and take the right prescription combinations and dosages of antihypertensive medications (Mancia et al., 2014), (Düsing, 2006). The severity and prevalence of the disease have led to the development of numerous synthetic medications for the treatment of hypertension. Although the majority of these medications have shown to be more effective, they are not without negative effects. Therefore, scientific research suggests a different approach to managing hypertension through dietary changes and the use of the right phytomedicine (Ajayi et al., 2019), (Singh et al., 2015). A growing number of people are turning to herbal remedies due to their accessibility, cultural acceptance, safety, efficacy, lack of adverse effects, and cost-effectiveness. Herbal remedies have recently received attention as alternate medicines for the treatment and prevention of cardiovascular issues (Sultana and Muhammad Asif, 2017), (Rastogi et al., 2016), (Nasri et al., 2014). Despite the availability of many modern antihypertensive medications, the majority of individuals still rely on complementary and alternative therapies, but some believe that combining these therapies with conventional therapies improves outcomes (Abubakar et al., 2015). Intensive study into local plants with hypotensive and antihypertensive therapeutic benefits has been conducted over the past three decades. Due to the lack of socioeconomic resources, low-income individuals in developing nations, particularly those who live in rural areas, have turned more and more to herbal remedies in an effort to manage HTN and its complications (Farnsworth et al., 1985). However, additional scientific investigation is required to confirm the efficacy and clarify the safety profile of such herbal therapies. An overview of the naturally occurring medicinal plants that have been investigated scientifically, and found to have hypotensive or antihypertensive properties is given in this review. Table 1 summarizes the information on the types of extracts, as well as the mechanisms of action, and references pertaining to the plants that have been studied or reported to have antihypertensive activity in animal studies.

Table 1 Some medicinal plants with anti-hypertensive activity.

S/N	Names of plants	Family	Part used	Mechanism of action	References
1	Achillea millefolium	Asteraceae	Flower	Calcium channel blockers and ACE inhibitors	(Arias-Durán et al., 2021)
2	Allium sativum	Alliaceae	Rhizome	Enhance nitric oxide production	(Nwokocha et al., 2011), (El-Saber Batiha et al., 2020)
3	Andrographis paniculata	Acanthaceae	Herbs	Increases NO, Inhibit ACE, Block calcium channels	(Cahyawati, 2021), (Verma et al., 2021)
4	Annona muricata	Annonaceae	Leaves, fruits	Reduce peripheral vascular resistance	(Sokpe et al., 2020), (Adefegha et al., 2015)
5	Apium graveolens	Apiaceae	Seeds	Calcium channels blocker.	(Makarova et al., 2022),
6	Aristolochia manshuriensis	Aristolochiaceae	Leaves	Diuretic	(Tabassum and Ahmad, 2011)
7	Artocarpus altilis	Moraceae	Leaves	ACE Inhibitors	(Siddesha et al., 2011)
8	Blond psyllium	Plantaginaceae	Roots / leaves	Lower systolic blood pressure	(Sharma et al., 2012)
9	Camellia sinensis (green Tea extracts)	Theaceae	Leaves	Inhibits ACE (AT1 receptor), Increases NO	(Xingfei et al., 2020)
10	Capparis cartilaginea	Capparaceae	Shrub	Calcium channels blocker	(Upadhyay, 2011), (Tabassum & Ahmad, 2011)
11	Carum copticum	Umbelliferae	Seeds	Increase NO production, Calcium channels blocker	(Gilani et al., 2005)
12	Cassia absus	Caesalpiaceae	Seeds	HR reduction through increased NO synthesis	(Ahmad et al., 2018)
13	Cassia	Caesalpiaceae	Leaves	An active diuretic.	(Ntchapda et al.,

	<i>occidentalis</i>				preventing Ca ²⁺ influx via voltage-sensitive and receptor-operated channels as well	(2015)
14	<i>Coleus forskohlii</i>	Lamiaceae			Relaxation of the vascular smooth muscle (enhance NO synthesis)	(Shivaprasad et al., 2014)
15	<i>Commelina virginica</i>	Commelinaceae	Leaves		Calcium channels blockers	(Khatoon et al., 2022)
16	<i>Coptis chinensis</i>	Ranunculaceae	Leaves / roots / stem		Calcium channels blocker	(Verma et al., 2021)
17	<i>Coriandrum sativum</i>	Apiaceae or Umbelliferae	Leaves		Diuretic action. By stimulating B-adrenoceptors, ROS generation is inhibited.	(Mahleyuddin et al., 2021)
18	<i>Crataegus pinnatifida</i>	Rosaceae	Leaves / roots.		Activates eNOS and inhibits platelet aggregation and thrombosis.	(Wang, et al., 2011),
19	<i>Crinum glaucum</i>	Amaryllidaceae	Leaves		Boost NO production. Reduce systolic and diastolic pressure.	(Ndjenda Ii et al., 2021)
20	<i>Crocus sativus</i>	Iridaceae	Roots / leaves		Blocks Ca ²⁺ Channels	(Hosseini et al., 2018), (Srivastava et al., 2010)
21	<i>Cymbopogon citratus</i>	Poaceae or Gramineae	Leaves		Inhibits Ca ²⁺ Influx. Increases NO bioavailability	(Dzeufiet et al., 2014)
22	<i>Daucus carota</i>	Umbelliferae	Arial part		Blockade of calcium channels	(Gilani et al., 2000)
23	<i>Desmodium styracifolium</i>	Leguminosae	Leaves		Stimulate of cholinergic receptors.	(Tabassum and Ahmad, 2011)
24	<i>Fuchsia magellanica</i>	Onagraceae	Leaves		ACE inhibitor. Acts as a diuretic.	(Hansen et al., 1995), (Kamyab et al., 2021)
25	<i>Gossypium barbadense</i>	Malvaceae	Leaves		Reduced the tension in an isolated guinea pig aorta induced by	(Rawat et al., 2016), (Baradaran et al., 2014), (Mans et al.,

				phenylephrine. Anti oxidant activity.	2010)
26	Hibiscus sabdariffa	Malvaceae	Leaves	Increases NO, Blocks Ca ²⁺ channels. Decrease plasma Na ⁺ Levels. Direct vasorelaxant actions that mediate through acetylcholine and histamine-like dependent mechanism.	(Baradaran et al., 2014), (Tabassum and Ahmad, 2011)
27	Jatropha gossypifolia	Euphorbiaceae		Calcium channels blocker.	(Silva et al., 2011), (Wu et al., 2019)
28	Laelia autumnalis	Orchidaceae	Roots	Calcium channels blocker	(Vergara-Galicia et al., 2010)
29	Lavandula stoechas	Lamiaceae	Leaves	The crude extract's antihypertensive and bradycardia effects may be mediated by a mechanism or mechanisms that are comparable to those of acetylcholine.	(Baradaran et al., 2014), (Tabassum and Ahmad, 2011), (Lim, 2014).
30	Lepechinia caulescens	Lamiaceae	Roots	Nitric oxide liberation	(Talha et al., 2011)
31	Lepidium latifolium	Cruciferae	Leaves	It exert diuretic action in rat	(Wright et al., 2007)
32	Lumnitzera racemose.	Combretaceae	Leaves	Calcium channels blocker. Enhance NO synthesis	(Das et al., 2022), (Manohar, 2021)
33	Lycopersicon esculentum	Solanaceae	Tomato fruits	Antioxidants activity. Slow the progress of atherosclerosis.	(Phachonpai, 2020)
34	Mammea Africana	Calophyllaceae	Bark	Ca ²⁺ antagonists	(Nguelefack-Mbuyo et al., 2008)
35	Moringa oleifera	Moringaceae	Leaves	Diuretic action, ACE inhibitor	(Kumolosasi et al., 2021), (Aekthammarat et

36	Musanga cecropiodes	Cecropiaceae	Leaves	Vasorelaxant action,	al., 2019), (Ma et al., 2021)
37	Ocimum basilicum	Lamiaceae	Leaves	. Eugenol's effects on the cardiovascular system are linked to its ability to inhibit calcium channels.	(Kamyab et al., 2021)
38	Olea europaea	Oleaceae	Leaves	Angiotensin II inhibition	(Baradaran et al., 2014), (Tabassum and Ahmad, 2011)
39	Phyllanthus niruri.	Euphorbiaceae	Leaves	Vasorelaxation and a drop in blood pressure are both mediated by - adrenoceptor activation.	(Ivanov et al., 2018), (Susalit et al., 2011)
40	Pinus pinaster	Pinaceae	Bark	ACE I	(Bello et al., 2020),
41	Pueraria lobate	Fabaceae	Roots	Vasodialation and antioxidant action	(Maimoona et al., 2011)
42	Punica granatum	Lythraceae	Fruits	Reduces ACEI action	(Ng et al., 2011), (Bebrevska et al., 2010)
43	Rauwolfia serpentine	Apocynaceae	Leaves / Roots	Deplete catecholamine	(Mayasankaravalli et al., 2020)
44	Rhaptopetalum coriaceum oliver	Scytometalaceae	Stem bark	Calcium channel blocker	(Kaur, 2017), (Shah et al., 2020)
45	Salvia cinnabarina	Lamiaceae	Leaves	Nitric oxide production	(Tabassum and Ahmad, 2011)
46	Sesamum indicum	Pedaliaceae	Seeds	Antioxidant activity	(Sultana and Muhammad Asif, 2017)
47	Solanum sisymbriifolium	Solanaceae	Roots	Diuretics	(Elleuch et al., 2011), (Mushtaq et al., 2020)
48	Tanacetum vulgare	Asteraceae	Leaves	Diuretic action. NO production enhancer	(Ibarrola et al., 2022)
49	Theobroma cacao	Malvaceae	Cacao powder	Antioxidant and calcium channels blocker	(Babich et al., 2023)

50	Uncaria rhynchophylla	Rubiaceae	Herbs	Calcium blocker	channel	(Loh et al., 2017), (Ndagijimana et al., 2013)
51	Viscum album	Santalaceae	Leaves	Enhances production	NO	(Poruthukaren et al., 2014)
52	Zingiber officinale	Zingiberaceae	Rhizome	Calcium blocker. Inhibits lipid peroxidation	channel	(Yeh et al., 2014), (Dhanik et al., 2017)

Conclusion

In recent years, there has been a resurgence of interest in the quest for novel medications derived from natural sources, particularly plant sources. Tropical rain forests have grown to be a key area of this activity, mostly because of the abundant biodiversity they support, which promises a wide variety of compounds with potentially unique structures. Nonetheless, only a small percentage of this diverse biodiversity has been investigated for its potential as medicine. As a result, in the future, we may be able to treat HTN with medications derived from plants and herbs that are naturally occurring and have fewer side effects and greater absorption.

NOTE:

The study highlights the efficacy of "herbal" which is an ancient tradition, used in some parts of India. This ancient concept should be carefully evaluated in the light of modern medical science and can be utilized partially if found suitable.

References

- Abubakar, M. G., Ukwuani, A. N., & Mande, U. U. (2015). Antihypertensive activity of Hibiscus Sabdariffa aqueous calyx extract in Albino rats. *Sky Journal of Biochemistry Research*, 4(3), 16–20.
- Adefegha, S. A., Oyeleye, S. I., & Oboh, G. (2015). Distribution of phenolic contents,

antidiabetic potentials, antihypertensive properties, and antioxidative effects of soursop (*Annona muricata* L.) fruit parts in vitro. *Biochemistry Research International*, 2015.

- Adeloye, D., Basquill, C., Aderemi, A. V., Thompson, J. Y., & Obi, F. A. (2015). An estimate of the prevalence of hypertension in Nigeria: a systematic review and meta-analysis. *Journal of Hypertension*, 33(2), 230–242.
- Aekthamarat, D., Pannangpetch, P., & Tangsucharit, P. (2019). Moringa oleifera leaf extract lowers high blood pressure by alleviating vascular dysfunction and decreasing oxidative stress in L-NAME hypertensive rats. *Phytomedicine*, 54, 9–16.
- Ahmad, S., Hassan, A., Abbasi, W. M., & Rehman, T. (2018). Phytochemistry and pharmacological potential of Cassia absus—a review. *Journal of Pharmacy and Pharmacology*, 70(1), 27–41.
- Ajayi, T. O., Moody, J. O., & Anthony, C. S. (2019). Ethnobotanical survey of plants used in the management of hypertension in Ibadan North Local Government Area of Oyo State, Nigeria. *Nigerian Journal of Pharmaceutical Research*, 15(1), 61–73.
- Anthony, J., & Sliwa, K. (2016). Decompensated heart failure in pregnancy. *Cardiac Failure Review*, 2(1), 20.
- Arias-Durán, L., Estrada-Soto, S., Hernández-Morales, M., Millán-Pacheco, C., Navarrete-Vázquez, G., Villalobos-Molina, R., Ibarra-Barajas, M., & Almanza-Pérez, J. C. (2021). Antihypertensive and vasorelaxant effect of leucodin and achillin isolated from *Achillea millefolium* through calcium channel blockade and NO production: In vivo, functional ex vivo and in silico studies. *Journal of Ethnopharmacology*, 273, 113948.
- Babich, O., Larina, V., Krol, O., Ulrikh, E., Sukhikh, S., Gureev, M. A., Prosekov, A., & Ivanova, S. (2023). In Vitro Study of Biological Activity of Tanacetum vulgare Extracts. *Pharmaceutics*, 15(2), 616.
- Baradaran, A., Nasri, H., & Rafieian-Kopaei, M. (2014). Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants. *Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences*, 19(4), 358.
- Barton, M., Husmann, M., & Meyer, M. R. (2016). Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy. *Canadian Journal of Cardiology*, 32(5), 680–686.
- Bebrevska, L., Foubert, K., Hermans, N., Chatterjee, S., Van Marck, E., De Meyer, G., Vlietinck, A., Pieters, L., & Apers, S. (2010). In vivo antioxidative activity of a quantified Pueraria lobata root extract. *Journal of Ethnopharmacology*, 127(1), 112–117.
- Bedane, S. N. (2018). Out of pocket expenditures among hypertensive patients and their households who visit public hospitals in Addis Ababa, Ethiopia, 2016. *Health Economics & Outcome Research: Open Access*, 4(1), 1–7.
- Bello, I., Usman, N. S., Dewa, A., Abubakar, K., Aminu, N., Asmawi, M. Z., & Mahmud, R. (2020). Blood pressure lowering effect and vascular activity of Phyllanthus niruri extract: The role of NO/cGMP signaling pathway and β -adrenoceptor mediated relaxation of isolated aortic rings. *Journal of Ethnopharmacology*, 250, 112461.

- Bowry, A. D. K., Lewey, J., Dugani, S. B., & Choudhry, N. K. (2015). The burden of cardiovascular disease in low-and middle-income countries: epidemiology and management. *Canadian Journal of Cardiology*, *31*(9), 1151–1159.
- Cahyawati, P. N. (2021). A Mini Review: Efek Farmakologi *Andrographis Paniculata* (Sambiloto). *WICAKSANA: Jurnal Lingkungan Dan Pembangunan*, *5*(1), 19–24.
- Das, S. K., Das, B., Jena, A. B., Pradhan, C., Sahoo, G., & Dandapat, J. (2022). Therapeutic Potential and Ethnopharmacology of Dominant Mangroves of Bhitarkanika National Park, Odisha, India. *Chemistry & Biodiversity*, *19*(3), e202100857.
- Desormais, I., Amidou, S. A., Houehanou, Y. C., Houinato, S. D., Gbagouidi, G. N., Preux, P. M., Aboyans, V., & Lacroix, P. (2019). The prevalence, awareness, management and control of hypertension in men and women in Benin, West Africa: the TAHES study. *BMC Cardiovascular Disorders*, *19*(1), 1–12.
- Dhanik, J., Arya, N., & Nand, V. (2017). A review on *Zingiber officinale*. *Journal of Pharmacognosy and Phytochemistry*, *6*(3), 174–184.
- Düsing, R. (2006). Overcoming barriers to effective blood pressure control in patients with hypertension. *Current Medical Research and Opinion*, *22*(8), 1545–1553.
- Dzeufiet, P. D. D., Mogueo, A., Bilanda, D. C., Aboubakar, B.-F. O., Tédong, L., Dimo, T., & Kamtchouing, P. (2014). Antihypertensive potential of the aqueous extract which combine leaf of *Persea americana* Mill.(Lauraceae), stems and leaf of *Cymbopogon citratus* (DC) Stapf.(Poaceae), fruits of *Citrus medica* L.(Rutaceae) as well as honey in ethanol and sucrose experiment. *BMC Complementary and Alternative Medicine*, *14*, 1–12.
- El-Saber Batiha, G., Magdy Beshbishy, A., G. Wasef, L., Elewa, Y. H. A., A. Al-Sagan, A., Abd El-Hack, M. E., Taha, A. E., M. Abd-Elhakim, Y., & Prasad Devkota, H. (2020). Chemical constituents and pharmacological activities of garlic (*Allium sativum* L.): A review. *Nutrients*, *12*(3), 872.
- Elleuch, M., Bedigian, D., & Zitoun, A. (2011). Sesame (*Sesamum indicum* L.) seeds in food, nutrition, and health. In *Nuts and seeds in health and disease prevention* (pp. 1029–1036). Elsevier.
- Fagard, R. H. (2011). Exercise therapy in hypertensive cardiovascular disease. *Progress in Cardiovascular Diseases*, *53*(6), 404–411.
- Farnsworth, N. R., Akerele, O., Bingel, A. S., Soejarto, D. D., & Guo, Z. (1985). Medicinal plants in therapy. *Bulletin of the World Health Organization*, *63*(6), 965.
- Ferder, L., Ferder, M. D., & Inserra, F. (2010). The role of high-fructose corn syrup in metabolic syndrome and hypertension. *Current Hypertension Reports*, *12*, 105–112.
- Ge, Z., Hao, Y., Cao, J., Li, J., Chen, J., Huang, J., Wu, X., & Gu, D. (2012). Does cigarette smoking exacerbate the effect of blood pressure on the risk of cardiovascular and all-cause mortality among hypertensive patients? *Journal of Hypertension*, *30*(12), 2307–2313.
- Ghadieh, A. S., & Saab, B. (2015). Evidence for exercise training in the management of hypertension in adults. *Canadian Family Physician*, *61*(3), 233–239.

- Gilani, A. H., Jabeen, Q., Ghayur, M. N., Janbaz, K. H., & Akhtar, M. S. (2005). Studies on the antihypertensive, antispasmodic, bronchodilator and hepatoprotective activities of the *Carum copticum* seed extract. *Journal of Ethnopharmacology*, 98(1–2), 127–135.
- Gilani, A. H., Shaheen, F., Saeed, S. A., Bibi, S., Sadiq, M., & Faizi, S. (2000). Hypotensive action of coumarin glycosides from *Daucus carota*. *Phytomedicine*, 7(5), 423–426.
- Guwatudde, D., Nankya-Mutyoba, J., Kalyesubula, R., Laurence, C., Adebamowo, C., Ajayi, I., Bajunirwe, F., Njelekela, M., Chiwanga, F. S., & Reid, T. (2015). The burden of hypertension in sub-Saharan Africa: a four-country cross sectional study. *BMC Public Health*, 15, 1–8.
- Hansen, K., Nyman, U., Smitt, U. W., Adersen, A., Gudiksen, L., Rajasekharan, S., & Pushpangadan, P. (1995). In vitro screening of traditional medicines for anti-hypertensive effect based on inhibition of the angiotensin converting enzyme (ACE). *Journal of Ethnopharmacology*, 48(1), 43–51.
- Holmqvist, L., Mortensen, L., Kanckos, C., Ljungman, C., Mehlig, K., & Manhem, K. (2012). Exercise blood pressure and the risk of future hypertension. *Journal of Human Hypertension*, 26(12), 691–695.
- Hosseini, A., Razavi, B. M., & Hosseinzadeh, H. (2018). Saffron (*Crocus sativus*) petal as a new pharmacological target: A review. *Iranian Journal of Basic Medical Sciences*, 21(11), 1091.
- Ibarrola, D. A., Arrua, W., Gonzalez, J. E., Escobar, M. S. S., Centurión, J., Benitez, A. M. C., Soria, F. M. O., González, E. I. R., Arrúa, K. G., & Barrios, M. B. A. (2022). The antihypertensive and diuretic effect of crude root extract and saponins from *Solanum sisymbriifolium* Lam., in L-NAME-induced hypertension in rats. *Journal of Ethnopharmacology*, 298, 115605.
- Ishaq, S., & Jafri, L. (2017). Biomedical importance of cocoa (*Theobroma cacao*): significance and potential for the maintenance of human health. *Matrix Science Pharma*, 1(1), 1–5.
- Ivanov, M., Vajic, U.-J., Mihailovic-Stanojevic, N., Miloradovic, Z., Jovovic, D., Grujic-Milanovic, J., Karanovic, D., & Dekanski, D. (2018). Highly potent antioxidant *Olea europaea* L. leaf extract affects carotid and renal haemodynamics in experimental hypertension: the role of oleuropein. *EXCLI Journal*, 17, 29.
- Kamyab, R., Namdar, H., Torbati, M., Ghojzadeh, M., Araj-Khodaei, M., & Fazljou, S. M. B. (2021). Medicinal plants in the treatment of hypertension: A review. *Advanced Pharmaceutical Bulletin*, 11(4), 601.
- Kaur, A. (2017). Pharmacobotanical and pharmacological evaluation of ayurvedic crude drug: *Rauwolfia serpentina* (Apocynaceae). *International Journal of Green Pharmacy (IJGP)*, 11(04).
- Khan, Q. A., Khan, A. A., Jabeen, A., Jahangir, U., Khalid, M., & Ansari, S. (2016). Essential hypertension: a co relational approach in Unani medicine. *Int J Pharmacogn*, 3(6), 240–245.
- Khaton, T., Naskar, A., Datta, K., Kumar, D., Kaur, G., Karmakar, P., & Pal, U. (2022). A Short Review on Role of Some Natural Herbs in the Treatment of Hypertension. *Asian*

Journal of Pharmaceutical Research and Development, 10(3), 88–93.

- Kovacs, G., Herve, P., Barbera, J. A., Chaouat, A., Chemla, D., Condliffe, R., Garcia, G., Grünig, E., Howard, L., & Humbert, M. (2017). An official European Respiratory Society statement: pulmonary haemodynamics during exercise. *European Respiratory Journal*, 50(5).
- Kumolosasi, E., Wei, C. C., Abdullah, A. Z., Abd Manap, N. S., Lee, W. L., Yousuf, M. H., Ying, L. S., Buang, F., Said, M. M., & Mohamad, H. F. (2021). Antihypertensive activities of standardised *Moringa oleifera* Lam.(merunggai) extracts in spontaneously hypertensive rats. *Sains Malays*, 50(3), 769–778.
- Le, M. T., Frye, R. F., Rivard, C. J., Cheng, J., McFann, K. K., Segal, M. S., Johnson, R. J., & Johnson, J. A. (2012). Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects. *Metabolism*, 61(5), 641–651.
- Li, W., Zhao, J., Song, L., Chen, S., Liu, X., & Wu, S. (2020). Combined effects of carotid plaques and hypertension on the risk of cardiovascular disease and all-cause mortality. *Clinical Cardiology*, 43(7), 715–722.
- Lim, T. K. (2014). *Lavandula stoechas*. In *Edible Medicinal and Non Medicinal Plants: Volume 8, Flowers* (pp. 192–201). Springer.
- Loh, Y. C., Ch'ng, Y. S., Tan, C. S., Ahmad, M., Asmawi, M. Z., & Yam, M. F. (2017). Mechanisms of action of *Uncaria rhynchophylla* ethanolic extract for its vasodilatory effects. *Journal of Medicinal Food*, 20(9), 895–911.
- Ma, K., Wang, Y., Wang, M., Wang, Z., Wang, X., Ju, X., & He, R. (2021). Antihypertensive activity of the ACE–renin inhibitory peptide derived from *Moringa oleifera* protein. *Food & Function*, 12(19), 8994–9006.
- Mahleyuddin, N. N., Moshawih, S., Ming, L. C., Zulkifly, H. H., Kifli, N., Loy, M. J., Sarker, M. M. R., Al-Worafi, Y. M., Goh, B. H., & Thuraisingam, S. (2021). *Coriandrum sativum* L.: A review on ethnopharmacology, phytochemistry, and cardiovascular benefits. *Molecules*, 27(1), 209.
- Maimoona, A., Naeem, I., Saddiqe, Z., & Jameel, K. (2011). A review on biological, nutraceutical and clinical aspects of French maritime pine bark extract. *Journal of Ethnopharmacology*, 133(2), 261–277.
- Makarova, E. I., Bokov, D. O., Sergunova, E. V., Chevidaev, V. V., Kakhramanova, S. D., Bessonov, V. V., Friesen, N. V., & Luferov, A. N. (2022). *Apium graveolens* L.: A phytochemical and pharmacological review. *Research Journal of Pharmacy and Technology*, 15(2), 927–934.
- Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., & Dominiczak, A. (2014). 2013 ESH/ESC practice guidelines for the management of arterial hypertension: ESH-ESC the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Blood Pressure*, 23(1), 3–16.

- Manohar, S. M. (2021). A Review of the Botany, Phytochemistry and Pharmacology of Mangrove *Lumnitzera racemosa* Willd. *Pharmacognosy Reviews*, 15(30).
- Mans, D. R. A., Sallevelt, S. C. E. H., Soekhoe, R., Bipat, R., & Toelsie, J. R. (2010). Evaluation of plants with presumed antihypertensive properties for their potential to decrease peripheral resistance using isolated guinea pig aortic rings pre-contracted with phenylephrine. *Academic Journal of Suriname*, 1(1), 15–19.
- Mayasankaravalli, C., Deepika, K., Lydia, D. E., Agada, R., Thagriki, D., Govindasamy, C., Chinnadurai, V., Gatar, O. M. O., Khusro, A., & Kim, Y. O. (2020). Profiling the phyto-constituents of *Punica granatum* fruits peel extract and accessing its in-vitro antioxidant, anti-diabetic, anti-obesity, and angiotensin-converting enzyme inhibitory properties. *Saudi Journal of Biological Sciences*, 27(12), 3228–3234.
- Mills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., Chen, J., & He, J. (2016). Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. *Circulation*, 134(6), 441–450.
- Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. *Nature Reviews Nephrology*, 16(4), 223–237.
- Mushtaq, A., Hanif, M. A., Ayub, M. A., Bhatti, I. A., & Jilani, M. I. (2020). Sesame. In *Medicinal Plants of South Asia* (pp. 601–615). Elsevier.
- Mv, S. P., & Mwinuka, V. J. (2021). Prevalence of Controlled Systemic Hypertension and its Associated Risk Factors among Hypertensive Patients at Mbeya Zonal Referral Hospital, Tanzania. *Systematic Reviews in Pharmacy*, 12(11), 3686–3690.
- Nandhini, S. (2014). Essential hypertension—a review article. *Journal of Pharmaceutical Sciences and Research*, 6(9), 305.
- Nasri, H., Baradaran, A., Shirzad, H., & Rafieian-Kopaei, M. (2014). New concepts in nutraceuticals as alternative for pharmaceuticals. *International Journal of Preventive Medicine*, 5(12), 1487.
- Ndagijimana, A., Wang, X., Pan, G., Zhang, F., Feng, H., & Olaleye, O. (2013). A review on indole alkaloids isolated from *Uncaria rhynchophylla* and their pharmacological studies. *Fitoterapia*, 86, 35–47.
- Ndjenda Ii, M. K., Nguelefack-Mbuyo, E. P., Atsamo, A. D., Fofie, C. K., Fodem, C., Nguemo, F., & Nguelefack, T. B. (2021). Antihypertensive Effects of the Methanol Extract and the Ethyl Acetate Fraction from *Crinum zeylanicum* (Amaryllidaceae) Leaves in L-NAME-Treated Rat. *Evidence-Based Complementary and Alternative Medicine*, 2021.
- Ng, C. F., Koon, C. M., Cheung, D. W. S., Lam, M. Y., Leung, P. C., Lau, C. B. S., & Fung, K. P. (2011). The anti-hypertensive effect of Danshen (*Salvia miltiorrhiza*) and Gegen (*Pueraria lobata*) formula in rats and its underlying mechanisms of vasorelaxation. *Journal of Ethnopharmacology*, 137(3), 1366–1372.
- Nguelefack-Mbuyo, P. E., Nguelefack, T. B., Dongmo, A. B., Afkir, S., Azebaze, A. G. B., Dimo, T., Legssyer, A., Kamanyi, A., & Ziyat, A. (2008). Anti-hypertensive effects of the methanol/methylene chloride stem bark extract of *Mammea africana* in L-NAME-induced

- hypertensive rats. *Journal of Ethnopharmacology*, 117(3), 446–450.
- Ntchapda, F., Barama, J., Azambou, D. R. K., Etet, P. F. S., & Dimo, T. (2015). Diuretic and antioxidant activities of the aqueous extract of leaves of *Cassia occidentalis* (Linn.) in rats. *Asian Pacific Journal of Tropical Medicine*, 8(9), 685–693.
- Nwokocha, C. R., Ozolua, R. I., Owu, D. U., Nwokocha, M. I., & Ugwu, A. C. (2011). Antihypertensive properties of *Allium sativum* (garlic) on normotensive and two kidney one clip hypertensive rats. *Niger J Physiol Sci*, 26(2), 213–218.
- Ogah, O. S., & Rayner, B. L. (2013). Recent advances in hypertension in sub-Saharan Africa. *Heart*, 99(19), 1390–1397.
- Phachonpai, W. (2020). Antihypertensive and vasoprotective effects of *Clausena lansium* fruits extract in L-NAME induced hypertensive rats. *Pakistan Journal of Pharmaceutical Sciences*.
- Pimenta, E., & Oparil, S. (2009). Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. *Vascular Health and Risk Management*, 453–463.
- Poruthukaren, K. J., Palatty, P. L., Baliga, M. S., & Suresh, S. (2014). Clinical evaluation of *Viscum album* mother tincture as an antihypertensive: a pilot study. *Journal of Evidence-Based Complementary & Alternative Medicine*, 19(1), 31–35.
- Princewel, F., Cumber, S. N., Kimbi, J. A., Nkfusai, C. N., Keka, E. I., Viyoff, V. Z., Beteck, T. E., Bede, F., Tsoka-Gwegweni, J. M., & Akum, E. A. (2019). Prevalence and risk factors associated with hypertension among adults in a rural setting: the case of Ombe, Cameroon. *The Pan African Medical Journal*, 34.
- Rastogi, S., Pandey, M. M., & Rawat, A. K. S. (2016). Traditional herbs: a remedy for cardiovascular disorders. *Phytomedicine*, 23(11), 1082–1089.
- Rawat, P., Singh, P. K., & Kumar, V. (2016). Anti-hypertensive medicinal plants and their mode of action. *Journal of Herbal Medicine*, 6(3), 107–118.
- Samadian, F., Dalili, N., & Jamalian, A. (2016). Lifestyle modifications to prevent and control hypertension. *Iranian Journal of Kidney Diseases*, 10(5).
- Saxena, T., Ali, A. O., & Saxena, M. (2018). Pathophysiology of essential hypertension: an update. *Expert Review of Cardiovascular Therapy*, 16(12), 879–887.
- Schutte, A. E., Srinivasapura Venkateshmurthy, N., Mohan, S., & Prabhakaran, D. (2021). Hypertension in low-and middle-income countries. *Circulation Research*, 128(7), 808–826.
- Shah, S. M. A., Naqvi, S. A. R., Munir, N., Zafar, S., Akram, M., & Nisar, J. (2020). Antihypertensive and antihyperlipidemic activity of aqueous methanolic extract of *Rauwolfia serpentina* in albino rats. *Dose-Response*, 18(3), 1559325820942077.
- Sharma, I., Parashar, B., Dhamija, H. K., & Sharma, R. (2012). An ayurvedic arena for hypertension treatment. *Asian Journal of Pharmaceutical Research*, 2(2), 54–58.
- Shivaprasad, H. N., Pandit, S., Bhanumathy, M., Manohar, D., Jain, V., Thandu, S. A., & Su, X. (2014). Ethnopharmacological and phytomedical knowledge of *Coleus forskohlii*: an

- approach towards its safety and therapeutic value. *Oriental Pharmacy and Experimental Medicine*, 14(4), 301–312.
- Siddesha, J. M., Angaswamy, N., & Vishwanath, B. S. (2011). Phytochemical screening and evaluation of in vitro angiotensin-converting enzyme inhibitory activity of *Artocarpus altilis* leaf. *Natural Product Research*, 25(20), 1931–1940.
- Silva, S. do N., Abreu, I. C., Freire, S. M. de F., Cartágenes, M. do S. de S., Ribeiro, R. M., Castro, A. S. de, Borges, A. C. R., & Borges, M. O. da R. (2011). Antispasmodic effect of *Jatropha gossypifolia* is mediated through dual blockade of muscarinic receptors and Ca²⁺ channels. *Revista Brasileira de Farmacognosia*, 21, 715–720.
- Singh, M., Mensah, G. A., & Bakris, G. (2010). Pathogenesis and clinical physiology of hypertension. *Cardiology Clinics*, 28(4), 545–559.
- Singh, P., Mishra, A., Singh, P., Goswami, S., Singh, A., & Tiwari, K. D. (2015). Hypertension and herbal plant for its treatment: a review. *Indian Journal of Research in Pharmacy and Biotechnology*, 3(5), 358.
- Sokpe, A., Mensah, M. L. K., Koffuor, G. A., Thomford, K. P., Arthur, R., Jibira, Y., Baah, M. K., Adedi, B., & Agbemenyah, H. Y. (2020). Hypotensive and antihypertensive properties and safety for use of *Annona muricata* and *Persea americana* and their combination products. *Evidence-Based Complementary and Alternative Medicine*, 2020, 1–13.
- Srivastava, R., Ahmed, H., Dixit, R. K., & Saraf, S. A. (2010). *Crocus sativus* L.: a comprehensive review. *Pharmacognosy Reviews*, 4(8), 200.
- Sultana, S., & Muhammad Asif, H. (2017). Medicinal plants combating against hypertension: A green antihypertensive approach. *Pakistan Journal of Pharmaceutical Sciences*, 30(6).
- Susalit, E., Agus, N., Effendi, I., Tjandrawinata, R. R., Nofiarny, D., Perrinjaquet-Moccetti, T., & Verbruggen, M. (2011). Olive (*Olea europaea*) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril. *Phytomedicine*, 18(4), 251–258.
- Tabassum, N., & Ahmad, F. (2011). Role of natural herbs in the treatment of hypertension. *Pharmacognosy Reviews*, 5(9), 30.
- Takahashi, H. (2008). Sympathetic hyperactivity in hypertension. *Nihon Rinsho. Japanese Journal of Clinical Medicine*, 66(8), 1495–1502.
- Talha, J., Priyanka, M., & Akanksha, A. (2011). Hypertension and herbal plants. *Int Res J Pharm*, 2(8), 26–30.
- Tuck, M. L. (1986). The sympathetic nervous system in essential hypertension. *American Heart Journal*, 112(4), 877–886.
- Upadhyay, R. K. (2011). Kareel plant: A natural source of medicines and nutrients. *International Journal of Green Pharmacy (IJGP)*, 5(4).
- Vergara-Galicia, J., Ortiz-Andrade, R., Rivera-Leyva, J., Castillo-España, P., Villalobos-Molina, R., Ibarra-Barajas, M., Gallardo-Ortiz, I., & Estrada-Soto, S. (2010). Vasorelaxant and antihypertensive effects of methanolic extract from roots of *Laelia anceps* are mediated by

calcium-channel antagonism. *Fitoterapia*, 81(5), 350–357.

Verma, T., Sinha, M., Bansal, N., Yadav, S. R., Shah, K., & Chauhan, N. S. (2021). Plants used as antihypertensive. *Natural Products and Bioprospecting*, 11, 155–184.

Viera, A. J. (2012). Resistant hypertension. *The Journal of the American Board of Family Medicine*, 25(4), 487–495.

Wang, T., Zhang, P., Zhao, C., Zhang, Y., Liu, H., Hu, L., Gao, X., & Zhang, D. (2011). Prevention effect in selenite-induced cataract in vivo and antioxidative effects in vitro of *Crataegus pinnatifida* leaves. *Biological Trace Element Research*, 142, 106–116.

Wright, C. I., Van-Buren, L., Kroner, C. I., & Koning, M. M. G. (2007). Herbal medicines as diuretics: a review of the scientific evidence. *Journal of Ethnopharmacology*, 114(1), 1–31.

Wu, Q., Patocka, J., Nepovimova, E., & Kuca, K. (2019). *Jatropha gossypifolia* L. and its biologically active metabolites: A mini review. *Journal of Ethnopharmacology*, 234, 197–203.

Xingfei, L., Shunshun, P., Wenji, Z., Lingli, S., Qiuhua, L., Ruohong, C., & Shili, S. (2020). Properties of ACE inhibitory peptide prepared from protein in green tea residue and evaluation of its anti-hypertensive activity. *Process Biochemistry*, 92, 277–287.

Yeh, H., Chuang, C., Chen, H., Wan, C., Chen, T., & Lin, L. (2014). Bioactive components analysis of two various gingers (*Zingiber officinale* Roscoe) and antioxidant effect of ginger extracts. *LWT-Food Science and Technology*, 55(1), 329–334.

Zhu, Y., Gu, X., & Xu, C. (2018). Mitochondrial DNA 7908–8816 region mutations in maternally inherited essential hypertensive subjects in China. *BMC Medical Genomics*, 11(1), 1–11.